Actively Recruiting
Evaluating Tislelizumab and SX-682 as Neoadjuvant Treatment for Surgically Removable Pancreatic Cancer
Led by Lei Zheng · Updated on 2026-10-07
25
Participants Needed
2
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and clinical activity of the drug combination of tislelizumab, an anti-PD-1 antibody, and SX-682, a CXCR12 inhibitor, in adults newly diagnosed with pancreatic adenocarcinoma that can be surgically removed. The study aims to understand how these drugs affect immune response and pathologic tumor changes in this specific group of patients. Participants will receive tislelizumab intravenously at 200 mg on Day 1 of six treatment cycles. The first two cycles last 14 days each, with cycle 1 before surgery and cycle 2 before standard chemotherapy. Cycles 3 to 6 each last 21 days and are given after completing chemotherapy. SX-682 is taken orally at 200 mg twice daily during days 1 to 14 of the first two cycles and days 1 to 21 of cycles 3 to 6, matching the same timing as tislelizumab. Participants will have tumor biopsies and multiple assessments including immune response measured by specific T cell markers at baseline and 2 weeks, and pathologic response assessed over four years. Safety will be monitored by tracking severe drug-related toxicities, overall survival, and disease-free survival during this period. The study involves regular evaluations to understand the treatment effects and long-term outcomes.
CONDITIONS
Brief Title
A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer
Research Team
E
Epp Goodwin
L
Lei Zheng, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here